Natera – Patient Worthy

Merck and Exelixis Team Up to Transform Treatment for High-Risk Colorectal Cancer Patients

Post author:Bree Clare
Post published:May 22, 2026
Post category:Colorectal cancer

Exelixis has taken a major step forward in its colorectal cancer development pipeline by securing supplies of Merck's Keytruda for an upcoming phase 3 clinical trial. As reported by Fierce…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More